scispace - formally typeset
J

James T. Rutka

Researcher at University of Toronto

Publications -  642
Citations -  34051

James T. Rutka is an academic researcher from University of Toronto. The author has contributed to research in topics: Epilepsy & Epilepsy surgery. The author has an hindex of 84, co-authored 618 publications receiving 30391 citations. Previous affiliations of James T. Rutka include Princeton University & Toronto Western Hospital.

Papers
More filters
Journal ArticleDOI

Nanoparticle-mediated cellular response is size-dependent

TL;DR: It is shown that gold and silver nanoparticles coated with antibodies can regulate the process of membrane receptor internalization and show that nanoparticles should no longer be viewed as simple carriers for biomedical applications, but can also play an active role in mediating biological effects.
Journal ArticleDOI

Medulloblastoma Comprises Four Distinct Molecular Variants

TL;DR: The authors' integrative genomics approach to a large cohort of medulloblastomas has identified four disparate subgroups with distinct demographics, clinical presentation, transcriptional profiles, genetic abnormalities, and clinical outcome.
Journal ArticleDOI

Current concepts: Nanomedicine

TL;DR: From the Institute of Biomaterials and Biomedical Engineering (B.Y.S.K., J.T.R., W.W.C.C.), Terrence Donnelly Centre for Cellular and Biomolecular Research, and the Department of Chemical Engineering.
Journal ArticleDOI

Mutations in SUFU predispose to medulloblastoma

TL;DR: It is reported that a subset of children with medulloblastoma carry germline and somatic mutations in SUFU (encoding the human suppressor of fused) of the SHH pathway, accompanied by loss of heterozygosity of the wildtype allele.
Journal ArticleDOI

Subgroup-specific structural variation across 1,000 medulloblastoma genomes

Paul A. Northcott, +139 more
- 02 Aug 2012 - 
TL;DR: Somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas are reported, including recurrent events targeting TGF-β signalling in Group 3, and NF-κB signalling in Groups 4, which suggest future avenues for rational, targeted therapy.